Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.

BACKGROUND: Recent studies on dialysis anticoagulation therapy in patients with renal failure have shown that Nafamostat mesylate, a broad-spectrum potent serine protease inhibitor, has strong anticoagulation and anti-fiber activity.

AIM: To evaluate the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.

METHODS: Seventy-five patients with end-stage renal failure who received hemodialysis at our hospital between January 2020 and August 2021 were selected and divided into the observation group (Nafamostat mesylate for injection, n = 33) and control group (heparin sodium injection, n = 32). General patient data, indicators of clinical efficacy, dialyzer hemocoagulation parameters, coagulation function indices, and hemoglobin concentration and platelet count before and after treatment, and the occurrence of adverse reactions after treatment were compared between the two groups.

RESULTS: The two groups showed no significant differences in general patient data ( P > 0.05). The post-treatment effectiveness rate in the control group was lower than that in the observation group ( P < 0.05). The two groups showed no significant difference in the number of patients in grade I ( P > 0.05), while the number of patients in grade 0 was lower in the control group, and the number of patients in grades II and III was higher in the control group ( P < 0.05). The post-treatment prothrombin time, activated partial thromboplastin time, thrombin time, and international normalized ratio values in the control group were higher than those in the observation group, while the fibrinogen level in the control group was lower than that in the observation group ( P < 0.05). The two groups showed no significant difference in the platelet count and hemoglobin level before and after treatment ( P > 0.05). The total number of post-treatment adverse reactions in the observation group was lower than that in the control group ( P < 0.05).

CONCLUSION: Treatment of patients showing end-stage renal failure with Nafamostat mesylate can significantly improve therapeutic efficacy and has high safety and clinical value.